Agios Pharmaceuticals Inc (Symbol: AGIO) has recently seen its shares trade at $54.41, surpassing the average analyst 12-month target price of $53.38. This shift indicates potential reevaluation by analysts, who may either downgrade their price estimates based on valuation or adjust them higher depending on the company’s performance.
Among eight analysts covering AGIO, target projections vary, with the lowest being $46 and the highest at $57, resulting in a standard deviation of $3.583. The current ratings breakdown shows five strong buy ratings, two buy ratings, and three hold ratings, with an average rating of 1.8 on a scale where 1 is a strong buy and 5 is a strong sell.
The implications of AGIO crossing the average target price have prompted investors to assess whether this is merely a plateau or a precursor to further gains.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
